Evercore Wealth Management LLC lessened its holdings in shares of Allergan plc (NYSE:AGN) by 5.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,822 shares of the company’s stock after selling 780 shares during the period. Evercore Wealth Management LLC’s holdings in Allergan were worth $2,443,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Edgewood Management LLC boosted its position in shares of Allergan by 1.5% during the third quarter. Edgewood Management LLC now owns 5,815,362 shares of the company’s stock valued at $1,107,710,000 after buying an additional 86,971 shares during the period. Franklin Resources Inc. boosted its position in shares of Allergan by 1.7% during the third quarter. Franklin Resources Inc. now owns 5,131,825 shares of the company’s stock valued at $977,516,000 after buying an additional 84,911 shares during the period. Janus Henderson Group PLC boosted its position in shares of Allergan by 16.3% during the second quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock valued at $796,712,000 after buying an additional 668,343 shares during the period. Northern Trust Corp boosted its position in shares of Allergan by 1.7% during the second quarter. Northern Trust Corp now owns 4,163,556 shares of the company’s stock valued at $694,149,000 after buying an additional 69,651 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Allergan by 2.6% in the third quarter. Bank of New York Mellon Corp now owns 3,637,854 shares of the company’s stock valued at $692,939,000 after purchasing an additional 92,297 shares during the period. Institutional investors and hedge funds own 78.24% of the company’s stock.

A number of analysts recently issued reports on the company. Cantor Fitzgerald reiterated a “hold” rating and issued a $180.00 price target on shares of Allergan in a report on Friday, September 14th. ValuEngine upgraded Allergan from a “sell” rating to a “hold” rating in a report on Tuesday, October 23rd. Piper Jaffray Companies set a $164.00 price target on Allergan and gave the company a “hold” rating in a report on Monday, September 17th. Wells Fargo & Co set a $232.00 price target on Allergan and gave the company a “buy” rating in a report on Wednesday, August 22nd. Finally, Cowen set a $255.00 price target on Allergan and gave the company a “buy” rating in a report on Wednesday, October 17th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $209.18.

In other Allergan news, CFO Matthew M. Walsh acquired 1,000 shares of Allergan stock in a transaction that occurred on Friday, November 16th. The stock was bought at an average price of $157.00 per share, with a total value of $157,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Shares of NYSE:AGN opened at $155.52 on Friday. The company has a market capitalization of $51.94 billion, a P/E ratio of 9.51, a price-to-earnings-growth ratio of 1.19 and a beta of 1.29. Allergan plc has a 52 week low of $142.81 and a 52 week high of $197.00. The company has a quick ratio of 0.78, a current ratio of 0.92 and a debt-to-equity ratio of 0.32.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, October 30th. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.21. The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a net margin of 14.50% and a return on equity of 8.44%. Allergan’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.15 earnings per share. On average, sell-side analysts predict that Allergan plc will post 16.52 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date of this dividend is Friday, November 9th. Allergan’s dividend payout ratio (DPR) is 17.61%.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/allergan-plc-agn-holdings-lessened-by-evercore-wealth-management-llc/2667318.html.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

See Also: What Factors Can Affect Return on Equity?

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.